Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.

Apostolia-Maria TsimberidouJamie V ShawDejan JuricClaire VerschraegenAmy M WeiseJohn SarantopoulosGilberto LopesJohn NemunaitisMonica MitaHaeseong ParkBarbara Ellers-LenzHui TianWenyuan XiongRemigiusz KaletaRazelle Kurzrock

Published in: Journal of hematology & oncology (2021)

M2698 was well tolerated. Combined with trastuzumab or tamoxifen, M2698 demonstrated antitumor activity in patients with advanced breast cancer resistant to multiple standard therapies, suggesting that it could overcome treatment resistance. Trial registration ClinicalTrials.gov, NCT01971515. Registered October 23, 2013.

Keyphrases

advanced cancer
palliative care
open label
clinical trial
signaling pathway
phase iii
epidermal growth factor receptor
cell proliferation
phase ii
breast cancer cells
positive breast cancer
double blind
placebo controlled
smoking cessation
breast cancer risk